Using Angiotensin II to Treat Vasoplegic Shock
Angiotensin II Stress Test. Renin Kinetics During Treatment of Vasoplegic Shock With Angiotensin II in Relation to Hemodynamic Response to Treatment With Angiotensin II.
This study is testing if giving angiotensin II can help adults with a specific type of shock improve their blood pressure and reduce the time they spend in the ICU.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 80 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Medical Centre Maribor Academic / other |
| Locations | 2 sites (Maribor and 1 other locations) |
| Trial ID | NCT06539234 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the effects of angiotensin II infusion in patients experiencing distributive shock who have not achieved adequate blood pressure despite receiving other vasopressors. Patients aged 18 and older with a specific type of shock will receive an angiotensin II infusion, and blood samples will be collected before and after treatment to measure renin levels. The primary focus is on the number of days free from organ failure and ICU stay, while secondary outcomes include the need for additional vasopressors and other interventions. The study aims to better understand the role of renin in shock severity and the effectiveness of angiotensin II in managing blood pressure.
Who should consider this trial
Good fit: Ideal candidates are adults with distributive shock lasting less than 72 hours who have not responded to standard vasopressor treatments.
Not a fit: Patients with severe comorbid conditions such as acute coronary syndrome or significant liver disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could improve blood pressure management in patients with vasoplegic shock and reduce the incidence of complications.
How similar studies have performed: Previous studies have indicated that angiotensin II can be effective in managing shock, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients with distributive shock lasting \< 72 hours * a goal mean arterial pressure (65-85 mmHg) not achieved despite an infusion of at least noradrenaline 0.3 mcg/kg/min and vasopressin 0.03 IE/min * the patient did not get angiotensin II before * predicted survival is \>24h * no limitations for active treatment Exclusion Criteria: * burns \>20% body area * acute coronary syndrome * bronchospasm * liver disease (MELD ≥30) * severe acute bleeding (need for 4 or more units of concentrated erythrocyte) * acute mesenteric ischemia * aortic dissection * leucopenia \<1000/mm3 * pregnancy * Raynaud disease, systemic sclerosis, vasospastic disease * the need for daily dose of hydrocortisone 500 mg or more * ECMO
Where this trial is running
Maribor and 1 other locations
- Medical ICU, University Medical Centre Maribor — Maribor, Slovenia (Recruiting)
- Surgical ICU, University Medical Centre Maribor — Maribor, Slovenia (Recruiting)
Study contacts
- Study coordinator: Andreja Möller Petrun, PhD
- Email: drejapet@web.de
- Phone: +38623211571
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.